Signal pathways of melanoma and targeted therapy

Area of Science:

• Oncology
• Dermatology
• Cancer Biology

Background:

• Melanoma, the deadliest skin cancer, arises from melanocyte transformation.
• Advances in targeted therapies and immunotherapy have improved melanoma patient prognosis.
• Treatment resistance and low response rates necessitate a deeper understanding of melanoma pathogenesis.

Purpose of the Study:

• To provide a comprehensive review of melanoma epidemiology, clinical features, risk factors, and current therapeutic strategies.
• To systematically discuss the signaling pathways involved in melanoma pathogenesis, including genetic mutations, epigenetic changes, metabolic reprogramming, and inflammatory pathways.
• To outline recent therapeutic advancements targeting driver genes and immune checkpoints, alongside mechanisms of treatment resistance.

Main Methods:

• Literature review and synthesis of current research on melanoma biology and therapy.
• Systematic discussion of key molecular pathways implicated in melanoma development and progression.
• Analysis of current treatment modalities, resistance mechanisms, and future therapeutic prospects.

Main Results:

• Melanoma pathogenesis is orchestrated by complex signaling pathways involving genetic mutations, epigenetic dysregulation, metabolic reprogramming, and inflammatory processes.
• Targeted therapies and immunotherapies have shown promise but face challenges with response rates and acquired resistance.
• Understanding these intricate mechanisms is key to developing more effective melanoma treatments.

Conclusions:

• Further comprehensive understanding of melanoma pathogenesis is essential for advancing therapeutic approaches.
• Overcoming treatment resistance and improving response rates require continued research into molecular mechanisms.
• Future melanoma therapy development, particularly in immunotherapy, holds significant promise for improved patient outcomes.